Global Monoclonal Antibodies Market Size To Worth USD 661.45 Billion by 2033 | CAGR Of 10.99%
Category: Food & BeveragesGlobal Monoclonal Antibodies Market Size To Worth USD 661.45 Billion by 2033
According to a research report published by Spherical Insights & Consulting, the Global Monoclonal Antibodies Market Size is to Grow from USD 233.25 Billion in 2023 to USD 661.45 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 10.99% during the projected period.
Get more details on this report -
Browse key industry insights spread across 195 pages with 140 Market data tables and figures & charts from the report on the "Global Monoclonal Antibodies Market Size, Share, and COVID-19 Impact Analysis By Source Type (Chimeric, Murine, Humanized, and Human), By Production Type (In Vivo and In Vitro), By Application (Oncology, Autoimmune Diseases, Infectious Diseases, Neurological Diseases, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." https://www.sphericalinsights.com/reports/monoclonal-antibodies-market
The class of proteins known as monoclonal antibodies (mAbs) is capable of binding to particular cells. These immunoglobulins are similar and come from a single B-cell that can identify the specific binding location on the antigen. A type of immunotherapy known as monoclonal antibodies involves the production of multiple copies of a single antibody in a lab. Depending on the source, monoclonal antibodies can be categorized as humanized, chimeric, murine, or humanized. Chimeric antibodies include human and murine components, whereas murine antibodies are made from a murine source. Human antibodies are created by combining many mouse or rat monoclonal antibodies with other human antibodies. One of the main factors driving the growth rate of the monoclonal antibody market is the rising incidence of cancer. Due to the rapidly expanding global market for monoclonal antibodies, many tumors in industrialized nations are being treated with monoclonal antibodies more and more frequently. Increased approval of blockbuster monoclonal antibodies (mAbs) for a range of applications, a rise in patient and physician awareness of the applications of mAb therapy, and a surge in research relationships for the development of a strong drug pipeline all contribute to the market growth. However, the market growth can be restricted by the high expenses of mAb development and the ensuing rise in the cost of mAb treatments.
The human segment is anticipated to hold the greatest share of the global monoclonal antibodies market during the projected timeframe.
On the basis of source type, the global monoclonal antibodies market is divided into chimeric, murine, humanized, and human. Among these, the human segment is anticipated to hold the greatest share of the global monoclonal antibodies market during the projected timeframe. It is expected that the manufacture of entirely human mAbs will become more popular quickly due to recent advancements in genetic engineering technology.
The in vitro segment is anticipated to hold the largest share of the global monoclonal antibodies market during the projected timeframe.
On the basis of production type, the global monoclonal antibodies market is divided into in vivo and in vitro. Among these, the in vitro segment is anticipated to hold the largest share of the global monoclonal antibodies market during the projected timeframe. In vitro manufacturing due to its reduced risk of contamination with external antigens and economic feasibility over extended production runs.
The oncology segment is predicted to hold the greatest share of the global monoclonal antibodies market during the estimated period.
On the basis of application, the global monoclonal antibodies market is divided into oncology, autoimmune diseases, infectious diseases, neurological diseases, and others. Among these, the oncology segment is predicted to hold the greatest share of the global monoclonal antibodies market during the estimated period. The oncology segment is responsible for a significant portion of the regulatory authorities approvals of monoclonal antibodies for use in cancer treatment.
North America is expected to hold the largest share of the global monoclonal antibodies market over the forecast period.
Get more details on this report -
North America is expected to hold the largest share of the global monoclonal antibodies market over the forecast period. Demand for monoclonal antibodies has increased in North America due to several factors, including a rise in the prevalence of chronic diseases, the region's sophisticated healthcare infrastructure, a rapidly aging population, high healthcare costs, and greater public awareness of mAbs.
Asia Pacific is predicted to grow at the fastest pace in the global monoclonal antibodies market during the projected timeframe. The Asia Pacific monoclonal antibodies market is anticipated to rise in the growing government investments in the construction of cutting-edge healthcare infrastructure and increased access to superior healthcare facilities.
Major vendors in the global monoclonal antibodies market include Thermo Fisher Scientific, Inc., Enzene Biosciences, Roche Pharma, Novartis AG, Pfizer Inc., GlaxoSmithKline plc., Merck & Co., Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca plc, Eli Lilly And Company, Johnson & Johnson Services, Inc., Bristol Myers Squibb, F. Hoffman-La Roche Ltd., and Others.
Recent Developments
- In July 2024, In a phase 2/3 clinical trial, Merck announced encouraging safety and efficacious outcomes regarding a monoclonal antibody it is creating to guard against respiratory syncytial virus (RSV) infection in babies.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global monoclonal antibodies market based on the below-mentioned segments:
Global Monoclonal Antibodies Market, By Source Type
- Murine
- Chimeric
- Humanized
- Human
Global Monoclonal Antibodies Market, By Production Type
- In Vivo
- In Vitro
Global Monoclonal Antibodies Market, By Application
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Neurological Diseases
- Others
Global Monoclonal Antibodies Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Uk
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?